HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers

Contributions of metabolic changes to cancer development and maintenance have received increasing attention in recent years. Although many human cancers share similar metabolic alterations, it remains unclear whether oncogene-specific metabolic alterations are required for tumor development. Using an RNAi-based screen targeting the majority of the known metabolic proteins, we recently found that oncogenic BRAF(V600E) up-regulates HMG-CoA lyase (HMGCL), which converts HMG-CoA to acetyl-CoA and a ketone body, acetoacetate, that selectively enhances BRAF(V600E)-dependent MEK1 activation in human cancer. Here, we identified HMG-CoA synthase 1 (HMGCS1), the upstream ketogenic enzyme of HMGCL, as an additional synthetic lethal partner of BRAF(V600E). Although HMGCS1 expression did not correlate with BRAF(V600E) mutation in human melanoma cells, HMGCS1 was selectively important for proliferation of BRAF(V600E)-positive melanoma and colon cancer cells but not control cells harboring activeN/KRAS mutants, and stable knockdown of HMGCS1 only attenuated colony formation and tumor growth potential of BRAF(V600E) melanoma cells. Moreover, cytosolic HMGCS1 that co-localized with HMGCL and BRAF(V600E) was more important than the mitochondrial HMGCS2 isoform in BRAF(V600E)-expressing cancer cells in terms of acetoacetate production. Interestingly, HMGCL knockdown did not affect HMGCS1 expression levels, whereas HMGCS1 knockdown caused a compensating increase in HMGCL protein level because of attenuated protein degradation. However, this increase did not reverse the reduced ketogenesis in HMGCS1 knockdown cells. Mechanistically, HMGCS1 inhibition decreased intracellular acetoacetate levels, leading to reduced BRAF(V600E)-MEK1 binding and consequent MEK1 activation. We conclude that the ketogenic HMGCS1-HMGCL-acetoacetate axis may represent a promising therapeutic target for managing BRAF(V600E)-positive human cancers.